With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).
Male or female participants aged ≥ 50 years;
Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);
Signed informed consent form
Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;
Inability to cooperate with cognitive assessments;
Refusal to undergo blood sampling.
AD, MCI, SCD and CN
Case-control
Cross-sectional
Multimodal Ophthalmic Imaging and plasma biomarker
Diagnostic testMultimodal Ophthalmic Imaging and plasma biomarkers (Aβ42/40, p-tau181, p-tau217, NfL and GFAP）.
Quantitative differences of core multimodal ophthalmic imaging parameters (including structural and functional ocular imaging indices) across study groups
Concentration difference of plasma biomarkers (Aβ42/40, p - tau181, p - tau217, NfL and GFAP） among groups
Click on the lead sponsor to view all of their trials.
